Antiplatelet therapy – a summary for the general physicians

Thachil, Jecko

doi:10.7861/clinmedicine.16-2-152

Cited by 46 publications

(27 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antiplatelet agents prevent platelet aggregation and are widely used in patients with coronary heart diseases and cerebrovascular events [25]. Different antiplatelet agents inhibit platelet aggregation through different mechanisms.…”

Section: Discussionmentioning

confidence: 99%

Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study

Lee

Chang

et al. 2019

JCM

View full text Add to dashboard Cite

While evidence is accumulating that platelets contribute to tissue destruction in tuberculosis (TB) disease, it is still not known whether antiplatelet agents are beneficial to TB patients. We performed this retrospective cohort study and identified incident TB cases in the Taiwan National Tuberculosis Registry from 2008 to 2014. These cases were further classified into antiplatelet users and non-users according to the use of antiplatelet agents prior to the TB diagnosis, and the cohorts were matched using propensity scores (PSs). The primary outcome was survival after a TB diagnosis. In total, 74,753 incident TB cases were recruited; 9497 (12.7%) were antiplatelet users, and 7764 (10.4%) were aspirin (ASA) users. A 1:1 PS-matched cohort with 8864 antiplatelet agent users and 8864 non-users was created. After PS matching, antiplatelet use remained associated with a longer survival (adjusted hazard ratio (HR): 0.91, 95% confidence interval (CI): 0.88–0.95, p < 0.0001). The risk of major bleeding was not elevated in antiplatelet users compared to non-users (p = 0.604). This study shows that use of antiplatelet agents has been associated with improved survival in TB patients. The immunomodulatory and anti-inflammatory effects of antiplatelet agents in TB disease warrant further investigation. Antiplatelets are promising as an adjunct anti-TB therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study

Lee

Chang

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Based on the joint consensus of several European and Asiatic scientific societies, Thachil advised stopping the second agent in dual antiplatelet therapy if the bleeding risk of a non-cardiac procedure was low 24. Similarly in a recent multidisciplinary consensus from Spain, Vivas et al .…”

Section: Discussionmentioning

confidence: 99%

Massive Hyphaema Following Laser Iridotomy in a Patient on Dual Antiplatelet Therapy (Aspirin plus Ticagrelor): Case report and literature review

Galvis

Tello

Carreño

et al. 2019

Sultan Qaboos Univ Med J

View full text Add to dashboard Cite

Massive hyphaema presentation after a laser iridotomy is very rare. We report a 63-year-old man with ischaemic heart disease on dual antiplatelet therapy (aspirin plus ticagrelor) who was diagnosed as a primary angle-closure suspect and was to undergo a neodymium-doped yttrium aluminium garnet laser iridotomy at Centro Oftalmológico Virgilio Galvis, Floridablanca, Colombia in 2016. While performing the iridotomy in the left eye, active bleeding occurred that finally filled approximately 75% of the anterior chamber. Intraocular pressure (IOP) increased to 62 mmHg. Mannitol and a topical dorzolamide/timolol were used to control the increase in IOP. The hyphaema slowly resolved over the following week without sequelae. This case revealed that massive hyphaema can complicate laser iridotomy in patients on dual antiplatelet therapy, although this is rare. Therefore, if patients are taking aspirin and ticagrelor, it would be advisable to stop the second medication if possible. In addition, sequential application of photocoagulation and photodisruption lasers might diminish the risk of significant bleeding.Keywords: Iridectomy; Nd-YAG Laser; Hyphema; Platelet Aggregation Inhibitors; Angle-Closure Glaucoma; Ocular Hypertension; Case Report; Columbia.

show abstract

“…Trombositlerin bir araya gelmeleri (agregasyonu), koroner ve periferik arter hastalıkları gibi arteriyel iskemik olayların ortaya çıkmasında ana sebeplerdendir. Bu sebeple antitrombosit tedavi bu hastalıkların önlenmesinde etkin rol oynamaktadır (Thachil, 2016). Antitrombosit tedavi amacıyla trombositler üzerinde bulunan glikoprotein IIb / IIIa yapıları hedef olarak belirlenmiştir (Breedveld, 2000).…”

Section: Antiplatelet Tedavisi (Antitrombosit Tedavi)unclassified

Monoklonal Antikorlar ve Tedavide Kullanımı

Kaya

Tutun

2021

Turkish JAF Sci.Tech.

View full text Add to dashboard Cite

Immune system is the basic defense system that protects the body against disease causing pathogens. The immun system use the most effective mechanisms and protects body against foreign materials called antigen. The antigens encounter primarily natural barriers. The antigens that cross natural barriers encounter immune cells in organs such as bone marrow, lymph nodes, spleen and thymus. In the first stage, macrophages and phagocytes become active, and in the next stage, B and T lymphocytes are involved in the process. Antibodies produced by B lymphocytes form one of the most important defense mechanism in immune system. This importance of antibody molecules in the immun system has led to scientists work in the field. In 1975, Georges Köhler and Cesar Milstein combined B lymphocytes from mice immunized with sheep red blood cells with the infinite growth of mouse myeloma cells to obtain monoclonal antibody-producing hybrid cells and paving the way for the development of therapeutic antibodies. This hybrid cells have ability to produce monoclonal antibodies just binding only to the desired antigen. Monoclonal antibodies have been used in many areas such as diagnosis, treatment and biochemical analysis of diseases worlwide. Nowadays, studies on monoclonal antibody-based treatment and treatment options are still ongoing. This review will focus on monoclonal antibodies and their uses in therapy.

show abstract

Antiplatelet therapy – a summary for the general physicians

Cited by 46 publications

References 62 publications

Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study

Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study

Massive Hyphaema Following Laser Iridotomy in a Patient on Dual Antiplatelet Therapy (Aspirin plus Ticagrelor): Case report and literature review

Monoklonal Antikorlar ve Tedavide Kullanımı

Contact Info

Product

Resources

About